A national cohort study of melanoma BRAF status, testing patterns, patient and tumour characteristics, treatment and survival in England from 2016 to 2021.

Br J Dermatol · 2025 · PMC12626136 · PMID 40902091

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Survival by BRAF status in stage I, III and IV tumours had overlapping CIs, but cohort numbers were smaller for these groups, and all but stage III tumours showed a trend towards worse outcomes in BRAF -mutated tumours.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.